Abstracts tagged "Cardiovascular"

Abstract Number: 0937 • ACR Convergence 2020
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Rahul Chanchlani¹, Anastasia Gayowsky², Sandeep Brar³, Elizabeth Darling⁴, Catherine Demers⁴, Tapas Mondal¹, Rulan Parekh⁵, Hsien Seow⁴ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²ICES McMaster, Hamilton, ON, Canada, ³University of California, San Fransisco, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Toronto, Canada
Background/Purpose: Kawasaki disease (KD) is a common childhood vasculitis associated with coronary artery aneurysms (CAA). Based on our recent work, the incidence of KD has…
Abstract Number: 1266 • ACR Convergence 2020
Multivariate Risk Model Shows Different Risk Factors for Myocardial Infarction and Stroke in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Cardiovascular events remain a major cause of morbidity and mortality in SLE. Accelerated atherosclerosis occurs in SLE and many other inflammatory diseases. In the…
Abstract Number: 1630 • ACR Convergence 2020
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
Lars Iversen¹, Christopher EM Griffiths², Andrea Peserico³, Ignasi Pau-Charles⁴, Andrew Blauvelt⁵, Diamant Thaçi⁶ and Kristian Reich⁷, ¹Aarhus University Hospital, Aarhus, Denmark, ²The University of Manchester, Manchester, United Kingdom, ³DIMED University of Padua, Padua, Italy, ⁴Almirall R&D, Barcelona, Spain, ⁵Oregon Medical Research Center, Portland, OR, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁷Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody that is approved for the treatment of moderate to severe plaque psoriasis. The objective of this…
Abstract Number: 0487 • ACR Convergence 2020
Association Between an Extended Lifestyle Score and Adverse Health-related Outcomes in People with Rheumatoid Arthritis: A Study of 5295 UK Biobank Participants
Jordan Canning¹, Stefan Siebert², Bhautesh Jani¹, Frances Mair¹ and Barbara Nicholl¹, ¹University of Glasgow, Glasgow, Scotland, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterised by inflammation of the synovial joints. Traditional lifestyle factors, such as smoking and poor diet,…
Abstract Number: 0950 • ACR Convergence 2020
The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders
Ken Cai¹, Billy Wu², Nicola Dalbeth², Rod Jackson² and Katrina Poppe², ¹University of Auckland, Sydney, New South Wales, Australia, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Some studies have reported that gout is an independent risk factor for cardiovascular disease (CVD). Individual-level cardiovascular risk prediction equations have been developed and…
Abstract Number: 1286 • ACR Convergence 2020
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
May Choi¹, Emma Stevens², Hongshu Guan², Daniel Li³, Jack Ellrodt⁴, Benjamin Kargere⁴, Tianrun Cai², Kazuki Yoshida⁵, Brendan Everett² and Karen Costenbader⁶, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Harvard, Columbus, OH, ⁴Williams College, Williamstown, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…
Abstract Number: 1658 • ACR Convergence 2020
Mediation of the Association Between Obesity and Osteoarthritis by Blood Pressure, Arterial Stiffness, and Subclinical Atherosclerosis
Marieke Loef¹, Rob van der Geest¹, Hildo Lamb¹, Renée de Mutsert¹, Frits Rosendaal¹ and Margreet Kloppenburg¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Obesity-related metabolic dysregulation may lead to atherosclerotic vascular changes. It has been hypothesized that a compromised blood flow may cause detrimental changes to the…
Abstract Number: 0496 • ACR Convergence 2020
A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease
David Patrick¹, Justin van Beusecum¹, Michelle Ormseth², Leslie J. Crofford², Sean Davies³, Sergey Dikalov¹ and David Harrison¹, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville
Background/Purpose: In SLE, cardiovascular complications are a significant contributor to morbidity and death. Importantly, there is an increased prevalence of hypertension in SLE patients compared…
Abstract Number: 1178 • ACR Convergence 2020
Associations of Walking Endurance and Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis
Genna Braverman¹, Sabahat Bokhari², Kazato Ito³, Joan Bathon² and Jon Giles⁴, ¹NY Presbyterian - Columbia University Irving Medical Center, New York, NY, ²Columbia University, Vagelos College of Physicians and Surgeons, New York, NY, ³Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁴Columbia University, New York, NY
Background/Purpose: The 400 meter timed walk test has been studied as a simple summary measure of fitness that is predictive of mobility limitation and incident…
Abstract Number: 1328 • ACR Convergence 2020
Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and troponin I (TnI) are established cardiac biomarkers that predict cardiovascular events (CVEs) and mortality in apparently healthy individuals…
Abstract Number: 1687 • ACR Convergence 2020
Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort
Monica Bray¹, Jennifer Rammel², Andrea Ramirez¹, Kristen Sexson¹, Fong Lam¹, Eyal Muscal³ and Marietta DeGuzman³, ¹Baylor College of Medicine, Houston, TX, ²University of Florida Health Jacksonville, Jacksonville, FL, ³Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD), a well described vasculitis of childhood, is the leading cause of acquired heart disease in developed countries. Kawasaki disease shock syndrome…
Abstract Number: 0503 • ACR Convergence 2020
Targeted Metabolomic Profiling and Prediction of Cardiovascular Events: A Prospective Study of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis and psoriasis, collectively termed psoriatic disease (PsD), are associated with increased cardiovascular (CV) risk. Metabolites comprise biomarkers that may add predictive value…
Abstract Number: 1179 • ACR Convergence 2020
Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study
Roxana Gonzalez Mazario¹, Jorge Juan Fragio Gil¹, Marta De la Rubia Navarro¹, Cristobal Pavez Perales¹, Samuel Leal Rodriguez², Jose Ivorra Cortes¹, Luis Gonzalez Puig³, Elena Grau Garcia², Elvira Vicens Bernabeu¹, F Ortiz-Sanjuan¹, Rosa Negueroles Albuixech¹, Cristina Alcañiz Escandell², Jose Eloy Oller Rodriguez¹, Inmaculada Chalmeta Verdejo¹, Isabel Martinez Cordellat¹, Carmen Najera Herranz¹, Ines Canovas Olmos¹, Antonio Cañada Martínez⁴ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain, ⁴HUP La Fe, Valencia, Spain
Background/Purpose: To assess the Cardiovascular Risk (CV) in Rheumatoid Arthritis (RA) patients using carotid ultasonography additionally to the traditional CV risk factors.Methods: A single center…
Abstract Number: 1330 • ACR Convergence 2020
Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study with 806 patients.
Inigo Gonzalez-Mazon¹, Javier Rueda-Gotor², Ivan Ferraz-Amaro³, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Fernanda Genre⁶, Natalia Palmou Fontana⁷, Vanesa Calvo-Río², Sara Remuzgo-Martínez⁶, Veronica Pulito-Cueto⁶, Alfonso Corrales⁸, Leticia Lera-Gómez⁶, Virginia Portilla⁶, Cristina Mata⁹, Vanesa Hernández-Hernández¹⁰, Santos Castañeda¹¹, Esther Francisca Vicente-Rabaneda¹², C Fernandez-Carballido¹³, M Paz Martínez-Vidal¹⁴, David Castro-Corredor¹⁵, Joaquín Anino-Fernández¹⁵, Juan Carlos Quevedo-Abeledo¹⁶, Carlos Rodríguez-Lozano¹⁷, María Luz García Vivar,¹⁸, Eva Galínez-Agirregoikoa¹⁸, C. Fernandez-Diaz¹⁹, Javier Llorca²⁰, Raquel López-Mejías⁶, Esther Montes-Perez²¹, Diana Peiteado²², Chamaida Plasencia²³, Alejandro Balsa-Criado²⁴, Nuria Barbarroja²⁵, Lourdes Ladehesa-Pineda²⁶, Rafaela Ortega-Castro²⁷, Eduardo Collantes-Estévez²⁶, Ricardo Blanco²⁸ and Miguel Ángel González-Gay²⁹, ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²H.U. Marques de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁶Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁷UNIVERSITARY HOSPITAL MARQUES VALDECILLA, Santander, Spain, ⁸Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital de Laredo, Santander, Spain, ¹⁰Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹¹Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ¹²Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ¹³H San Juan, Alicante, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹⁶Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁷Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁸Hospital Universitario Basurto, Bilbao, Spain, ¹⁹H. Marqués de Valdecilla, Madrid, Spain, ²⁰School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ²¹Diagnóstico Médico Cantabria (DMC), Santander, Spain, ²²Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ²³Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ²⁴HOSPITAL UNIVERSITARIO LA PAZ, madrid, Spain, ²⁵Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ²⁷Hospital Universitario Reina Sofía, Córdoba, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²⁹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) as compared to the general population. Carotid plaque, considered as a surrogate marker…
Abstract Number: 1689 • ACR Convergence 2020
Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
Abdulrahman Alkanhal¹, Joseph Saunders², Fajer Altammar³, Adam Huber⁴, Andrew Lynk², Alison MacLeod⁵, Oliva Ortiz-Alvarez⁶, Meighan Adams², Suzanne Ramsey⁷, Elizabeth Stringer⁸, Andrew Warren² and Bianca Lang⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Dalhousie University, Halifax, Canada, ³Mcmaster University, Hamilton, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Annapolis Valley Health, Kentville, Canada, ⁶St Martha's Regional Hospital, Antigonish, Canada, ⁷IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ⁸IWK Health Centre, Halifax, NS, Canada, ⁹Dalhousie University - Halifax, Halifax, NS, Canada
Background/Purpose: Kawasaki Disease (KD), a systemic vasculitis of unknown etiology, is now the leading cause of acquired heart disease in children in North America. Its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.